ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$2.19
+0.22 (+11.17%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| EPS | — | — | — |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| Rev Growth | +12.9% | -8.9% | -3.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 41.92M | 48.16M | 40.49M |
| Total Equity | 120.15M | 125.42M | 118.16M |
| D/E Ratio | 0.35 | 0.38 | 0.34 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |